IncantheraAQSE:INC Days Payable is 89,333.75 as of Sep. 2025. The stock has 2 warning signs investors should review. Among 700 Biotechnology companies, Incanthera ranks better than 99.43% on this metric.
Incanthera's average Accounts Payable for the
six
months ended in Sep. 2025 was £0.49 Mil. Incanthera's Cost of Goods Sold for the
six
months ended in Sep. 2025 was £0.00 Mil.
Hence, Incanthera's Days Payable for the
six
months ended in Sep. 2025 was 89,333.75.
The historical rank and industry rank for Incanthera's Days Payable or its related term are showing as below:
AQSE:INC'
s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 180553.33
Current: 180553.33
During the past 6 years, Incanthera's highest Days Payable was 180553.33. The lowest was 0.00. And the median was 0.00.
AQSE:INC's Days Payable is ranked better than 99.43% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs AQSE:INC: 180553.33
Incanthera's Days Payable
increased
from Sep. 2024 (0.00) to Sep. 2025 (89,333.75).
It may suggest that Incantheradelayed paying its suppliers.
Incanthera Days Payable Related Terms
Incanthera Days Payable Historical Data
* Premium members only.
The historical data trend for Incanthera's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AQSE:INC vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Incanthera's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incanthera Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incanthera's Days Payable distribution charts can be found below:
* The bar in red indicates where Incanthera's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Incanthera's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incanthera (AQSE:INC) has a Days Payable of 89,333.75 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Incanthera and its competitors. According to the industry distribution chart, Incanthera ranks #4 out of 700 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Incanthera's Days Payable too high?
Incanthera's current Days Payable is 89,333.75. The Biotechnology industry median Days Payable is 112.83. Incanthera's value of 89,333.75 is 79075.5% above this industry median. Based on the distribution chart, Incanthera ranks #4 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Incanthera's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Incanthera ranks #4 out of 700 companies for Days Payable. This places Incanthera in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.83. Incanthera's value of 89,333.75 is 79075.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incanthera's current Days Payable of 89,333.75 is 79075.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Incanthera and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incanthera's current Days Payable is 89,333.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incanthera stock overvalued right now?
Incanthera (AQSE:INC) has a current Days Payable of 89,333.75. The current Days Payable is 89,333.75 and 79075.5% above the Biotechnology industry median of 112.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Incanthera (AQSE:INC), the current Days Payable is 89,333.75 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incanthera PLC is clinical stage drug development. It specializes in dermatology and oncology therapeutics. The company has launched a skincare range called Skin + CELL, which addresses and enhances life quality through effective delivery of bioactive ingredients capable of energising the skin's natural repair and defence processes at the cellular level. It has one reportable segment, namely the development of dermatology and pharmaceutical products, within the United Kingdom and Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:INC has been successfully added to your 